Active	Status	Sponsor type	Region	Phase	Filter
5 Active 5 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Sloan, Andrew E
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022 Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022 Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022 Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022 Data from P1 part of P1/2 XPORT-MF-034 trial for myelofibrosis at ASH 2022 Nov 2022 - Nov 2022: Data from P1 part of P1/2 XPORT-MF-034 trial for myelofibrosis at ASH 2022 Preliminary data from P1 part of P1/2 XPORT-MF-034 trial in combination with ruxolitinib for myelofibrosis at ASCO 2022 Jun 2022 - Jun 2022: Preliminary data from P1 part of P1/2 XPORT-MF-034 trial in combination with ruxolitinib for myelofibrosis at ASCO 2022 Data from P1 study in combination with ruxolitinib in 1L myelofibrosis at ASCO 2022 May 2022 - May 2022: Data from P1 study in combination with ruxolitinib in 1L myelofibrosis at ASCO 2022 More	Recruiting	3	350	Europe, Canada, US, RoW	Selinexor, KPT-330, Placebo, Ruxolitinib	Karyopharm Therapeutics Inc	Myelofibrosis	09/25	03/28
TVI-AST-008, NCT05685004: Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)	Recruiting	2/3	120	US	TVI-Brain-1, Standard of Care, Radiotherapy, Temozolomide, Chemotherapy	TVAX Biomedical	Glioblastoma Multiforme of Brain	12/26	03/27
ImmuneSense, NCT04485949: A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma	Active, not recruiting	2	93	US	IGV-001 Cell Immunotherapy, Placebo, Standard of Care (SOC): Radiation Therapy, SOC: Temozolomide	Imvax	Glioblastoma	01/25	07/27